NCT03925714RecruitingPhase 3
Impact of P53 and SIRT1 in Type 2 Diabetes
Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin
Source: ClinicalTrials.gov · Last updated 24 Apr 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Investigating the impact of p53 and SIRT1 in the development of type 2 DM
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 22 Apr 2019
- Start date
- 1 Apr 2019
- Primary completion date
- Dec 2028
- Lead sponsor
- Sherief Abd-Elsalam
- Diseases
- Type 2 diabetes
- NCT number
- NCT03925714
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 90
- From 1 Apr 2019 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Confirmed diabetes.
- Hepatic or renal impairment.
Who the study is looking for
- Prediabetic subjects.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sherief Abd-Elsalam Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.